Doubling time of serum CA125 is an independent prognostic factor for survival in patients with ovarian cancer relapsing after first-line chemotherapy.
Han
Liz Y
LY
Gynecology Unit, Royal Marsden Hospital, London and Surrey, UK.
Karavasilis
Vasilios
V
Hagen
Tom van
Tv
Nicum
Shibani
S
Thomas
Karen
K
Harrison
Michelle
M
Papadopoulos
Panagiotis
P
Blake
Peter
P
Barton
Desmond P J
DP
Gore
Martin
M
Kaye
Stan B
SB
D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000704:Analysis of Variance; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000008:administration & dosage*; D018394:CA-125 Antigen / Q000097:blood*; D018450:Disease Progression; D005260:Female; D006801:Humans; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000097:blood* / Q000175:diagnosis; D010051:Ovarian Neoplasms / Q000097:blood* / Q000188:drug therapy / Q000401:mortality; D011379:Prognosis; D015996:Survival Rate; D013997:Time Factors
D018394:CA-125 Antigen